Table S1: Study eligibility criteria

|  |  |
| --- | --- |
| Criteria | Description |
| **Population** | * Adult advanced (stage III/IV) NCSLC Cancer Patients of any/all race/ethnicity with any/all of the following genomic alterations: * *EGFR* * *ALK* * *ROS1* * *BRAF* * *NTRK1/2/3* * *RET* * *MET* * PD-L1 * *KRAS* * Wildtype * Unknown driver mutation |
| **Interventions** | Any of the following technologies for detection of targetable genomic alterations:   * ctDNA-based genomic profiling * Tissue-based genomic profiling   AND, when outcome of interest is clinical utility:   * At least 80% of population receiving Standard of Care by driver mutation (according to current NCCN Guidelines, table on page 92 of version 3.2022) defined as:   + *EGFR* Exon 19 deletion or L858R: afatinib or erlotinib or dacomitinib or gefitinib or osimertinib or ramucirumab or bevacizumab;   + *EGFR* S768I or L861Q, and/or G719X: afatinib, or erlotinib, or dacomitinib, or gefitinib, or osimertinib;   + *EGFR* Exon 20 insertion mutation positive: amivantamab-vmjw or mobocertinib;   + *ALK* rearrangement positive: alectinib or brigatinib or certinib or crizotinib or lorlatinib   + *ROS1* rearrangement positive: certinib or crizotinib or entrectinib   + *BRAF* V600E mutation positive: dabrafenib/trametinib or vemurafenib   + *NTRK*1/2/3: Larotrectinib or entrectinib   + *RET*: selpercatinib or pralsetinib or cabozantinib   + *MET*: capmatinib or crizotinib or tepotinib   + *KRAS*: sotorasib   + PD-L1: pembrolizumab or carboplatin or cisplatin or pemetrexed or paclitaxel or bevacizumab or atezolizumab or albumin-bound paclitaxel or nivolumab or ipilimumab   + Wildtype:   [NOTE: Studies must contain two or more driver genes (e.g., EGFR and ALK) in order to be included] |
| **Outcomes** | * Clinical validity   + Sensitivity;   + Specificity; or   + Positive/negative predictive value   OR   * Clinical utility   + Progression free survival; or   + Overall survival, reported as KM or survival curve |
| **Study design** | * Prospective or retrospective cohort studies * Randomized controlled trials |
| **Language** | * English |
| **Time** | * Only studies published from year 2012 onward |

Table S2: Search strategy with Medline, Embase - searched within Embase platform (on 7/5/2023)

|  |  |  |  |
| --- | --- | --- | --- |
| **No.** | **Criteria** | **Strings** | **Hits** |
| 1 | Population | 'non small cell lung cancer'/exp OR 'non small cell lung cancer' OR nsclc | 226949 |
| 2 | Population | egfr OR 'epidermal growth factor receptor' | 275762 |
| 3 | Population | alk OR 'anaplastic lymphoma receptor tyrosine kinase' | 27898 |
| 4 | Population | ros1 OR 'ros proto-oncogene 1 receptor tyrosine kinase' | 5689 |
| 5 | Population | braf OR 'b-raf proto-oncogene, serine/threonine kinase' | 43312 |
| 6 | Population | ntrk1 OR 'neurotrophic receptor tyrosine kinase 1' | 2063 |
| 7 | Population | ntrk2 OR 'neurotrophic receptor tyrosine kinase 2' | 1162 |
| 8 | Population | ntrk3 OR 'neurotrophic receptor tyrosine kinase 3' | 1762 |
| 9 | Population | ret OR 'ret proto-oncogene' | 18947 |
| 10 | Population | met OR 'met proto-oncogene, receptor tyrosine kinase' | 420609 |
| 11 | Population | kras OR 'kras proto-oncogene' | 49111 |
| 12 | Population | 'pd-l1' OR 'programmed death-ligand 1' | 51488 |
| 13 | Population | 'genomic alterat\*' | 12040 |
| 14 | Population | wildtype | 355241 |
| 15 | Population | #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 | 1162656 |
| 16 | Population | #1 AND #15 | 71563 |
| 17 | Intervention | 'genomic profiling' OR 'genetic profiling' OR 'molecular profil\*' OR 'tumor profil\*' OR 'mutation profil\*' OR 'molecular test' OR 'biomarker test\*' OR 'tumor sequenc\*' | 38880 |
| 18 | Intervention | 'liquid biopsy' OR 'fluid biopsy' OR 'cell free dna' OR cfdna OR 'circulating tumor dna' OR 'ctdna' | 34466 |
| 19 | Intervention | 'tissue biopsy' OR 'needle biopsy' | 67521 |
| 20 | Intervention | #17 OR #18 OR #19 | 136618 |
| 21 | Outcomes | 'clinical validity' | 3332 |
| 22 | Outcomes | sensitivity' | 1800575 |
| 23 | Outcomes | 'specificity' | 1078876 |
| 24 | Outcomes | 'positive predictive value' | 77283 |
| 25 | Outcomes | 'negative predictive value' | 68402 |
| 26 | Outcomes | #21 OR #22 OR #23 OR #24 OR #25 | 2264504 |
| 27 | Outcomes | 'clinical utility' | 50221 |
| 28 | Outcomes | 'progression free survival' OR 'pfs' | 206013 |
| 29 | Outcomes | 'overall survival' OR 'os' | 627143 |
| 30 | Outcomes | #27 OR #28 OR #29 | 733394 |
| 31 | Outcomes | #26 OR #30 | 2945799 |
| 32 | Study design | 'retrospective study' OR 'prospective study' OR 'observational study' OR 'cohort analysis' OR 'real world evidence' OR 'register' OR 'electronic health record' OR 'electronic medical record' | 3307459 |
| 33 | Study design | 'clinical trial' OR 'randomized controlled trial' OR 'controlled clinical trial' | 2259219 |
| 34 | Study design | 'single arm trial' | 1825 |
| 35 | Study design | #32 OR #33 OR #34 | 5169692 |
| 36 |  | #16 AND #20 AND #31 AND #35 | 1920 |
| 37 | Limits | #36 AND [english]/lim | 1916 |
| 38 | Limits | #37 AND (2012:py OR 2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py OR 2020:py OR 2021:py OR 2022:py) | 1749 |

Table S3. Patient characteristics in included clinical validity (CV) studies (n=18)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **No. of Patients** | **Tumor stage III/IV (advanced)** | **Age (years)** | **Male** | **Former/Current Smokers** | **Caucasian** | **Asian** | **African American** | **Hispanic** |
| **Author\_Year** | n | % | Median (range) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| Bustamante Alvarez\_2021 | 94 | 100 | NA | NA | NA | NA | NA | NA | NA |
| Fernandes\_2021 | 115 | 100 | 66 (38-92) | 71 (61.7%) | 73 (63.5%) | NA | NA | NA | NA |
| Leighl\_2019 | 282 | 100 | 69 (26-100) | 129 (45.7%) | 214 (76.1%) | 231 (81.9%) | 17 (6%) | 18 (6.4%) | 23 (8.2%) |
| Li\_2019 | 127 | 100 | NA | 47 (37%) | NA | NA | NA | NA | NA |
| Lin\_2021 | 100 | 98 | 67.5 (35-92) | 44 (44%) | NA | NA | NA | NA | NA |
| Müller\_2017 | 98 | 54.1 | mean=66 | 43 (44%) | NA | NA | NA | NA | NA |
| Palmero\_2021 | 186 | 100 | 63.4 (39-86) | 121 (65%) | 132 (71%) | 180 (97%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Park\_2021 | 262 | 100 | 62 (30-89) | 175 (66.8%) | 155 (59.2%) | NA | NA | NA | NA |
| Pritchett\_2019 | 264 | 100 | mean=67.1 (SD=11) | 128 (48.5%) | 225 (85.2%) | 226 (85.6%) | 6 (2.3%) | 26 (9.8%) | 0 (0%) |
| Schwaederlé\_2017 | 88 | 100 | 66.2 (36.3-89.5) | 30 (34%) | 50 (56.8%) | 58 (66%) | 18 (20.5%) | 1 (1.1%) | 2 (2.3%) |
| Yao\_2017 | 39 | 100 | 62 (28-78) | 19 (48.7%) | 10 (25.6%) | NA | NA | NA | NA |
| Xu\_2016 | 42 | 100 | 62 (37-75) | 21 (50%) | NA | NA | NA | NA | NA |
| Liu\_2018 | 72 | 100 | 59 (40-83) | 44 (61.1%) | 29 (40.3%) | NA | NA | NA | NA |
| Couraud\_2014 | 106 | 87.5 | Mean=68.7 (SD=13.7) | 13 (12.3%) | 0 | NA | NA | NA | NA |
| Chen\_2019 | 50 | 40 | NA | 35 (70%) | 21 (42%) | NA | NA | NA | NA |
| Remon\_2019 | 214 | 100 | Mean=63.7 (SD=10.53) | 126 (58.9%) | 175 (83.3%) | NA | NA | NA | NA |
| Guo\_2016 | 41 | 26.8 (IV) | 52 (38-73) | 22 (53.7%) | NA | NA | NA | NA | NA |
| Sabari\_2019 | 210 | 100 | 65 (28-91) | 86 (41%) | NA | NA | NA | NA | NA |

Table S4. Data included in meta-analysis on the clinical validity (CV) of ctDNA testing for multi-gene detection (n=13)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of Patients** | **Test driver genes** | **TP** | **FP** | **FN** | **TN** | **Total No. of Samples** |
| Bustamante Alvarez\_2021 | 94 | Overall (*EGFR*, *ALK* fusions, *BRAF*, *MET* exon 14 skipping mutation, *ROS1* mutations and *RET* fusions) | 22 | 7 | 11 | 54 | 94 |
| Fernandes\_2021 | 127 | Overall (Oncomine – *EGFR, KRAS, ALK, BRAF, MET, ROS1, ERBB2, MAP2K1, NRAS, PIK3CA*, and *TP53*) | 51 | 3 | 12 | 61 | 127 |
| Leighl\_2019 | 282 | Overall (*EGFR, ALK* fusion, *BRAF* V600E, *MET* amplification, *MET* exon 14 skipping, *ROS1* fusion, *RET* fusion, *ERBB2* mutation) | 35 | 0 | 9 | 862 | 906 |
| Li\_2019 | 91 for sensitivity analysis; 19 for specificity analysis | Overall (*EGFR, KRAS, ALK, BRAF, MET, ROS1, RET, ERBB2*) | 68 | 0 | 23 | 789 | 880 |
| Müller\_2017 | 29 | Key 6 genes (*EGFR, KRAS, ALK, BRAF, ROS1, TP53*) | 16 | 1 | 12 | 145 | 174 |
| Park\_2021 | 262 | Key genes (*EGFR* Del 9, *EGFR* L858R, *KRAS*, *ALK*, *BRAF* V600E, *MET* exon 14, *MET* amplification, *ROS1*, *RET*, *ERBB2* exon 20) | 95 | 19 | 69 | 2437 | 2620 |
| Pritchett\_2019 | 95 | Key 8 genes (*EGFR* (exons 18-21), *KRAS*, *ALK/ROS1*, *BRAF* V600E, *MET* exon 14, *ERBB2* exon 20, *STK11*) | 88 | 2 | 31 | 1027 | 1148 |
| Yao\_2017 | 39 | Overall (EGFR, KRAS, PIK3CA, ALK and gene fusions (EML4-ALK and KIF5B-RET)) | 19 | 0 | 9 | 128 | 156 |
| Xu\_2015 | 42 | Key genes (*EGFR, KRAS, BRAF, ERBB2, PIK3CA, TP53*) | 23 | 25 | 7 | 197 | 252 |
| Liu\_2017 | 72 | Overall (*EGFR* L858R, *EGFR* exon 19 del, *KRAS* G12X, *ALK* rearrangement) | 34 | 1 | 16 | 222 | 273 |
| Couraud\_2014 | 50 | All 12 amplicons together (*EGFR* (exons 18-21), *KRAS* (exons 2 & 3), *BRAF* (exons 11 & 15), *ERBB2* (exons 19 & 20), *PI3KCA* (exons 9 & 20)) | 24 | 1 | 22 | 489 | 536 |
| Remon\_2019 | 94 | Core gene variants (*EGFR* (exons 18-21), *KRAS, BRAF* V600E, *MET* exon 14, *ERBB2* exon 20, *STK11*) | 35 | 10 | 8 | 320 | 373 |
| Sabari\_2019 | 106 | *Key genes (EGFR, KRAS, ALK, BRAF, MET, ROS1, RET)* | 44 | 7 | 35 | 656 | 742 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative

Figure S1. Bayesian Posterior Predictive Contours (50%, 75%, 95%) of ctDNA testing for multi-gene detection (n=13)

A graph with a red line and blue dots

Description automatically generated

Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S5. Results from frequentist and Bayesian bivariate random effects meta-analyses

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | Frequentist Approach | | Bayesian Approach | | |
|  | No. of studies | Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | BAUC |
| Overall | 13 | 0.69(0.63, 0.74) | 0.99 (0.97, 1.00) | 0.70 (0.60, 0.79) | 0.99 (0.97, 1.00) | 0.71 (0.68, 0.73) |
| *EGFR* | 14 | 0.68 (0.62, 0.74) | 0.98 (0.95, 0.99) | 0.70 (0.60, 0.78) | 0.98 (0.95, 0.99) | 0.71 (0.68, 0.73) |
| *KRAS* | 11 | 0.77 (0.63, 0.86) | 0.96 (0.90, 0.98) | 0.82 (0.70, 0.90) | 0.97 (0.93, 0.99) | 0.72 (0.69, 0.73) |
| *BRAF* | 8 | 0.60 (0.39, 0.77) | 0.99 (0.99, 1.00) | 0.64 (0.37, 0.86) | 1.00 (0.99, 1.00) | 0.53 (0.51, 0.54) |
| *ALK* | 6 | 0.59 (0.45, 0.73) | 0.99 (0.98, 1.00) | 0.60 (0.38, 0.79) | 0.99 (0.98, 1.00) | 0.62 (0.58, 0.64) |
| *ROS1* | 4 | 0.29 (0.13, 0.53) | 0.99 (0.97, 1.00) | 0.26 (0.06, 0.58) | 0.99 (0.97, 1.00) | 0.67 (0.52, 0.73) |
| *MET* | 5 | 0.47 (0.33, 0.62) | 0.98 (0.97, 0.99) | 0.48 (0.26, 0.71) | 0.99 (0.97, 1.00) | 0.70 (0.63, 0.73) |
| *RET* | 3 | 0.38 (0.21, 0.58) | 0.99 (0.97, 1.00) | 0.37 (0.11, 0.71) | 0.98 (0.95, 1.00) | 0.66 (0.50, 0.73) |

Table S6. Data included in meta-analysis on the clinical validity (CV) of ctDNA detection of *EGFR* (n=14)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Leighl\_2019 | 223 | 27 | 0 | 5 | 414 |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 29 | 0 | 8 | 73 |
| Müller\_2017 | 29 | 6 | 0 | 1 | 22 |
| Palmero\_2021 | 148 | 24 | 0 | 12 | 112 |
| Park\_2021 | 262 | 35 | 4 | 14 | 471 |
| Pritchett\_2019 | 164 | 13 | 0 | 5 | 146 |
| Schwaederlé\_2017 | 26 | 7 | 2 | 3 | 14 |
| Yao\_2017 | 39 | 12 | 0 | 5 | 22 |
| Xu\_2015 | 42 | 4 | 11 | 3 | 24 |
| Liu\_2017 | 72 | 26 | 0 | 12 | 106 |
| Couraud\_2014 | 45 | 19 | 1 | 8 | 147 |
| Chen\_2019 | 7 | 2 | 0 | 1 | 4 |
| Remon\_2019 | 94 | 7 | 1 | 1 | 78 |
| Sabari\_2019 | 106 | 24 | 1 | 20 | 61 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative

Figure S2. Forest plot of sensitivity and specificity on ctDNA detection of *EGFR* from bivariate random effects meta-analyses (n=14)

A screenshot of a table

Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations; I2 = 0% based on the frequentist approach

Figure S3. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of *EGFR* (n=14)

1. SROC (frequentist approach):

A diagram of a diagram

Description automatically generated with medium confidence

1. SROC (Bayesian approach):

A diagram of a graph

Description automatically generated

Figure S4. Bayesian Posterior Predictive Contours (50%, 75%, 95%) for ctDNA detection of *EGFR* (n=14)

A graph with a red circle and blue dots

Description automatically generated

Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S7. Data included in meta-analysis on the CV of ctDNA detection of *KRAS* (n=11)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Bustamante Alvarez\_2021 | 94 | 69 | 9 | 2 | 14 |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 23 | 0 | 6 | 81 |
| Müller\_2017 | 29 | 4 | 0 | 5 | 20 |
| Park\_2021 | 262 | 23 | 3 | 11 | 225 |
| Pritchett\_2019 | 146 | 48 | 1 | 12 | 86 |
| Yao\_2017 | 39 | 3 | 0 | 1 | 35 |
| Xu\_2015 | 42 | 6 | 6 | 0 | 30 |
| Liu\_2017 | 65 | 6 | 0 | 2 | 57 |
| Couraud\_2014 | 45 | 2 | 0 | 1 | 82 |
| Remon\_2019 | 94 | 22 | 7 | 3 | 56 |
| Sabari\_2019 | 106 | 8 | 2 | 10 | 86 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative

Figure S5. Forest plot of sensitivity and specificity on ctDNA detection of *KRAS* from bivariate random effects meta-analyses (n=11)

A screenshot of a graph

Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations; I2 = 0% based on the frequentist approach

Figure S6. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of *KRAS* (n=11)

1. SROC (frequentist approach)

A diagram of a positive rate

Description automatically generated

1. SROC (Bayesian approach)

A graph with blue dots

Description automatically generated

Figure S7. Bayesian Posterior Predictive Contours (50%, 75%, 95%) for ctDNA detection of *KRAS* (n=11)

A graph with a red line and blue dots

Description automatically generated

Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S8. Data included in meta-analysis on the CV of ctDNA detection of *BRAF* (n=8)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Leighl\_2019 | 92 | 2 | 0 | 0 | 90 |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 3 | 0 | 0 | 107 |
| Müller\_2017 | 29 | 0 | 0 | 1 | 28 |
| Park\_2021 | 262 | 1 | 1 | 2 | 258 |
| Pritchett\_2019 | 151 | 5 | 2 | 0 | 140 |
| Couraud\_2014 | 44 | 0 | 0 | 2 | 86 |
| Remon\_2019 | 94 | 1 | 0 | 1 | 75 |
| Sabari\_2019 | 106 | 3 | 0 | 0 | 103 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative

Figure S8. Forest plot of sensitivity and specificity on ctDNA detection of *BRAF* from bivariate random effects meta-analyses (n=8)

A screenshot of a graph

Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations; I2 = 0% based on the frequentist approach

Figure S9. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of *BRAF (*n=8)

1. SROC (frequentist approach):

A graph of a test results

Description automatically generated with medium confidence

1. SROC (Bayesian approach):

A graph with blue dots and numbers

Description automatically generated

Figure S10. Bayesian Posterior Predictive Contours (50%, 75%, 95%) for ctDNA detection of *BRAF* (n=8)

A graph with dots and lines

Description automatically generated

Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S9. Data included in meta-analysis on the CV of ctDNA detection of *ALK* (n=6)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Leighl\_2019 | 215 | 6 | 0 | 2 | 207 |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 5 | 0 | 3 | 102 |
| Palmero\_2021 | 132 | 2 | 1 | 3 | 126 |
| Park\_2021 | 262 | 6 | 0 | 4 | 252 |
| Liu\_2017 | 64 | 2 | 1 | 2 | 59 |
| Sabari\_2019 | 106 | 4 | 1 | 2 | 99 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative

Figure S11. Forest plot of sensitivity and specificity on ctDNA detection of *ALK* from bivariate random effects meta-analyses (n=6)

A screenshot of a graph

Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations; I2 = 10.9% based on the frequentist approach

Figure S12. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of *ALK* (n=6)

1. SROC (frequentist approach):

A graph of a data

Description automatically generated with medium confidence

1. SROC (Bayesian approach):

A graph of a function

Description automatically generated with medium confidence

Figure S13. Bayesian Posterior Predictive Contours (50%, 75%, 95%) for ctDNA detection of *ALK* (n=6)

A graph with numbers and a red line

Description automatically generated

Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S10. Data included in meta-analysis on the CV of ctDNA detection of *ROS1* (n=4)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Leighl\_2019 | 153 | 0 | 0 | 2 | 151 |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 1 | 0 | 2 | 107 |
| Park\_2021 | 262 | 3 | 0 | 12 | 247 |
| Sabari\_2019 | 106 | 1 | 2 | 1 | 102 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative

Figure S14. Forest plot of sensitivity and specificity on ctDNA detection of *ROS1* from bivariate random effects meta-analyses (n=4)

A screenshot of a graph

Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations; I2 = 0% based on the frequentist approach

Figure S15. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of *ROS1* (n=4)

1. SROC (frequentist approach)

1. SROC (Bayesian approach):

A graph of a function

Description automatically generated with medium confidence

A graph of a function

Description automatically generated

Figure S16. Bayesian Posterior Predictive Contours (50%, 75%, 95%) for ctDNA detection of *ROS1* (n=4)

A graph with a red line and blue dots

Description automatically generated

Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S11. Data included in meta-analysis on the CV of ctDNA detection of *MET* (n=5)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 3 | 0 | 3 | 104 |
| Park\_2021 | 262 | 8 | 9 | 11 | 496 |
| Pritchett\_2019 | 140 | 3 | 0 | 3 | 133 |
| Remon\_2019 | 94 | 1 | 0 | 2 | 45 |
| Sabari\_2019 | 106 | 3 | 0 | 1 | 102 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative

Figure S17. Forest plot of sensitivity and specificity on ctDNA detection of *MET* from bivariate random effects meta-analyses (n=5)

A screenshot of a graph

Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations; I2 = 7.3% based on the frequentist approach

Figure S18. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of *MET* (n=5)

1. SROC (frequentist approach):

A graph of a positive rate

Description automatically generated with medium confidence

1. SROC (Bayesian approach):

A graph of a function

Description automatically generated with medium confidence

Figure S19. Bayesian Posterior Predictive Contours (50%, 75%, 95%) for ctDNA detection of *MET* (n=5)

Chart, scatter chart

Description automatically generated

Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S12. Data included in meta-analysis on the CV of ctDNA detection of *RET* (n=3)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 0 | 0 | 1 | 109 |
| Park\_2021 | 262 | 7 | 2 | 12 | 241 |
| Sabari\_2019 | 106 | 1 | 1 | 1 | 103 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative

Figure S20. Forest plot of sensitivity and specificity on ctDNA detection of *RET* from bivariate random effects meta-analyses (n=3)

A screenshot of a graph

Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations; I2 = 0% based on the frequentist approach

Figure S21. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of *RET* (n=3)

1. SROC (frequentist approach):

A graph of a positive rate

Description automatically generated

1. SROC (Bayesian approach):

A graph of a function

Description automatically generated with medium confidence

Figure S22. Bayesian posterior predictive contours (50%, 75%, 95%) for ctDNA detection of *RET* (n=3)

A graph with red circle and blue dots

Description automatically generated


Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S13. Data included in meta-analysis on the CV of ctDNA detection of SNV mutation class(n=11)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Leighl\_2019 | 223 | 11 | 0 | 1 | 303 |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 26 | 0 | 6 | 188 |
| Müller\_2017 | 29 | 4 | 0 | 6 | 48 |
| Park\_2021 | 262 | 44 | 5 | 21 | 716 |
| Pritchett\_2019 | 164 | 55 | 1 | 14 | 226 |
| Yao\_2017 | 39 | 12 | 0 | 4 | 179 |
| Xu\_2015 | 42 | 9 | 19 | 2 | 96 |
| Liu\_2017 | 72 | 22 | 0 | 7 | 108 |
| Couraud\_2014 | 45 | 2 | 0 | 3 | 168 |
| Chen\_2019 | 7 | 1 | 0 | 0 | 4 |
| Remon\_2019 | 94 | 23 | 7 | 4 | 131 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative; SNV: single nucleotide variant or polymorphism, including 1) *EGFR* L858R, T790M, L861Q, G719S, and other unspecified *EGFR* SNVs, 2) *KRAS* G12X and other unspecified *KRAS* SNVs, 3) *BRAF* V600E and other unspecified *BRAF* SNVs

Figure S23. Forest plot of sensitivity and specificity on ctDNA detection of SNVsfrom bivariate random effects meta-analyses (n=11)



Sensitivity and specificity of single studies were based on frequentist estimations.

I2 = 0% based on the frequentist approach; BAUC = 0.72 (95%CI: 0.70-0.74)

Figure S24. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of SNV mutation class (n=11)

1. SROC (frequentist approach):

Chart, diagram

Description automatically generated

1. SROC (Bayesian approach):





Figure S25. Bayesian posterior predictive contours (50%, 75%, 95%) for ctDNA detection of SNV mutation class(n=11)



Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S14. Data included in meta-analysis on the CV of ctDNA detection of indel mutation class(n=6)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Leighl\_2019 | 223 | 18 | 0 | 4 | 201 |
| Park\_2021 | 262 | 15 | 3 | 6 | 238 |
| Yao\_2017 | 39 | 4 | 0 | 2 | 33 |
| Xu\_2015 | 42 | 1 | 1 | 1 | 39 |
| Liu\_2017 | 72 | 10 | 0 | 7 | 55 |
| Chen\_2019 | 7 | 1 | 0 | 1 | 4 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative; indels include *EGFR* exon 19 del or other unspecified *EGFR* indels

Figure S26. Forest plot of sensitivity and specificity on ctDNA detection of indelsfrom bivariate random effects meta-analyses (n=6)

Table


Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations.

I2 = 3.3% based on the frequentist approach; BAUC = 0.52 (95%CI: 0.48-0.54)

Figure S27. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of indel mutation class (n=6)

1. SROC (frequentist approach):




1. SROC (Bayesian approach):

Chart

Description automatically generated

Figure S28. Bayesian posterior predictive contours (50%, 75%, 95%) for ctDNA detection of indel mutation class(n=6)



Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S15. Data included in meta-analysis on the CV of ctDNA detection of fusion mutation class(n=5)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author\_Year** | **No. of patients** | **TP** | **FP** | **FN** | **TN** |
| Leighl\_2019 | 223 | 6 | 0 | 4 | 358 |
| Li\_2019 | 91 for sensitivity analysis, 19 for specificity analysis | 6 | 0 | 6 | 318 |
| Liu\_2017 | 72 | 2 | 1 | 2 | 59 |
| Palmero\_2021 | 132 | 2 | 1 | 3 | 126 |
| Park\_2021 | 262 | 16 | 2 | 28 | 740 |

TP: true positive; FP: false positive; FN: false negative; TN: true negative; fusions include ALK, ROS1 and RET

Figure S29. Forest plot of sensitivity and specificity on ctDNA detection of fusionsfrom bivariate random effects meta-analyses (n=5)

Graphical user interface, application

Description automatically generated

Sensitivity and specificity of single studies were based on frequentist estimations.

I2 = 0% based on the frequentist approach; BAUC = 0.52 (95%CI: 0.47-0.54)

Figure S30. Summary receiver operating characteristics (SROC) plots based on bivariate random-effects meta-analyses of ctDNA detection of fusion mutation class (n=5)

1. SROC (frequentist approach):

Diagram

Description automatically generated

1. SROC (Bayesian approach):

Chart

Description automatically generated

Figure S31. Bayesian posterior predictive contours (50%, 75%, 95%) for ctDNA detection of fusion mutation class(n=5)

Chart

Description automatically generated

Each purple circle identifies the true positive rate (TPR) vs. the false positive rate (FPR) of each study (observed data). Light blue circles are predictions based on Bayesian meta-analysis of data by fitting a bivariate random effects model, with red lines indicating parametric predictive contours.

Table S16. Quality assessment of studies by QUADAS-2

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study ID** | **Risk of Bias** | | | | **Applicability Concerns** | | |
| Patient selection | Index Test(s) | Reference Standard | Flow and Timing | Patient selection | Index Test(s) | Reference Standard |
| Bustamante Alvarez\_2021 | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ | ☹ |
| Fernandes\_2021 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Leighl\_2019 | ☺ | ☺ | ☹ | ☺ | ☺ | ☺ | ☺ |
| Li\_2019 | ☹ | ☹ | ☺ | ☹ | ☺ | ☹ | ☺ |
| Lin\_2021 | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ | ☹ |
| Müller\_2017 | ☺ | ? | ☺ | ☹ | ☹ | ☺ | ☺ |
| Palmero\_2021 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Park\_2021 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Pritchett\_2019 | ☺ | ☺ | ☺ | ☹ | ☺ | ? | ☺ |
| Schwaederlé\_2017 | ? | ☹ | ☹ | ☹ | ☹ | ? | ☺ |
| Yao\_2017 | ☺ | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ |
| Xu\_2016 | ? | ? | ☺ | ☺ | ? | ? | ☺ |
| Liu\_2018 | ☺ | ☺ | ☺ | ☺ | ☺ | ? | ☺ |
| Couraud\_2014 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Chen\_2019 | ? | ? | ☺ | ☺ | ☹ | ? | ☺ |
| Remon\_2019 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Guo\_2016 | ? | ? | ☺ | ☺ | ☹ | ? | ☺ |
| Sabari\_2019 | ☺ | ☺ | ☺ | ☺ | ? | ☺ | ☺ |

☺Low Risk ☹High Risk ? Unclear Risk